Equities research analysts predict that Jounce Therapeutics Inc (NASDAQ:JNCE) will announce $2.34 earnings per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Jounce Therapeutics’ earnings, with estimates ranging from $1.83 to $2.70. Jounce Therapeutics posted earnings of ($0.23) per share in the same quarter last year, which indicates a positive year over year growth rate of 1,117.4%. The business is scheduled to issue its next quarterly earnings report on Tuesday, November 12th.
On average, analysts expect that Jounce Therapeutics will report full year earnings of $1.66 per share for the current financial year, with EPS estimates ranging from $1.12 to $2.28. For the next financial year, analysts expect that the business will post earnings of ($2.87) per share, with EPS estimates ranging from ($3.90) to ($1.27). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Jounce Therapeutics.
Jounce Therapeutics (NASDAQ:JNCE) last announced its earnings results on Wednesday, August 7th. The company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.05. Jounce Therapeutics had a negative net margin of 46.07% and a negative return on equity of 29.64%. The business had revenue of $17.45 million during the quarter, compared to analysts’ expectations of $17.09 million.
Several large investors have recently made changes to their positions in JNCE. Assenagon Asset Management S.A. raised its holdings in shares of Jounce Therapeutics by 479.5% in the first quarter. Assenagon Asset Management S.A. now owns 278,100 shares of the company’s stock valued at $1,724,000 after buying an additional 230,109 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Jounce Therapeutics by 30.8% in the second quarter. Vanguard Group Inc. now owns 800,150 shares of the company’s stock valued at $3,961,000 after buying an additional 188,540 shares during the last quarter. Acadian Asset Management LLC increased its stake in shares of Jounce Therapeutics by 108.3% during the first quarter. Acadian Asset Management LLC now owns 291,533 shares of the company’s stock worth $1,807,000 after acquiring an additional 151,576 shares during the period. Strs Ohio acquired a new position in shares of Jounce Therapeutics during the second quarter worth about $470,000. Finally, Dupont Capital Management Corp acquired a new position in shares of Jounce Therapeutics during the second quarter worth about $321,000. 73.54% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ:JNCE traded up $0.02 on Friday, reaching $3.96. The company’s stock had a trading volume of 178,500 shares, compared to its average volume of 327,194. The stock’s 50-day moving average is $4.43 and its two-hundred day moving average is $5.03. Jounce Therapeutics has a 52-week low of $2.66 and a 52-week high of $8.58. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.03 and a quick ratio of 2.03. The stock has a market capitalization of $135.55 million, a P/E ratio of -4.71 and a beta of 3.44.
About Jounce Therapeutics
Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform.
Further Reading: What is Green Investing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.